

转化生长因子 β II 型受体在胃癌组织中表达的研究

张朋彬, 李宜辉, 徐采朴

张朋彬, 李宜辉, 中国人民解放军第三军医大学新桥医院消化内科
重庆市 400037
徐采朴, 中国人民解放军第三军医大学西南医院消化内科 重庆市 400038
张朋彬, 男, 1966-04-13 生, 汉族, 河北省宁晋县人. 1999 年第三军医大学
新桥医院消化内科博士毕业, 主要从事消化道疾病的诊治.
项目负责人: 张朋彬, 400037, 重庆市新桥, 中国人民解放军第三军医大学新
桥医院消化内科. zpb666@sina.com
电话: 023-68774665
收稿日期: 2004-02-11 接受日期: 2004-02-18

Expression of transforming growth factor β type II receptor in gastric carcinoma tissue

Peng-Bin Zhang, Yi-Hui Li, Cai-Pu Xu

Peng-Bin Zhang, Yi-Hui Li, Department of Gastroenterology, Xinqiao
Hospital, Third Military Medical University, Chongqing 400037, China
Cai-Pu Xu, Department of Gastroenterology, Southwest Hospital, Third
Military Medical University, Chongqing 400038, China
Correspondence to: Peng-Bin Zhang, Department of Gastroenterology,
Xinqiao Hospital, Third Military Medical University, Chongqing 400037,
China. zpb666@sina.com
Received: 2004-02-11 Accepted: 2004-02-18

Abstract

AIM: To investigate the expression of transforming growth factor β type II receptor (TGF β IIIR) in the gastric carcinoma tissue.

METHODS: Expression of TGF β IIIR was studied in 20 cases of normal gastric tissues and 74 gastric carcinoma tissues by immunohistochemical method.

RESULTS: In normal gastric tissue, TGF β IIIR was mainly expressed in the lower part of the gland, especially in the cytoplasm, and the expression was significantly decreased in well and moderately differentiated adenocarcinoma tissues ($P < 0.05$), and in poorly differentiated and mucinous or signet ring cell carcinoma tissues ($P < 0.01$) as compared with normal mucosa.

CONCLUSION: Decreased expression of TGF β IIIR may play a role in the development of gastric cancer.

Zhang PB, Li YH, Xu CP. Expression of transforming growth factor β type II receptor in gastric carcinoma tissue. *Shijie Huaren Xiaohua Zazhi* 2004;12(7):1531-1533

摘要

目的: 研究转化生长因子 β (TGF β)II型受体在胃癌组织中的表达及其意义.

方法: 应用免疫组织化学方法, 对20例正常胃粘组织及74例胃癌组织(高中分化腺癌 32 例, 低分化腺癌 23 例, 黏

液腺癌 14 例, 印戒细胞癌 5 例) TGF β II 型受体的表达情况进行了研究.

结果: 在正常胃黏膜组织, TGF β II 型受体主要表达于腺体的体底部; 在胃高中分化腺癌组织中, TGF β II 型受体表达减少($P < 0.05$, vs 正常胃黏膜); 在低分化腺癌及黏液印戒细胞癌中, 其表达明显减少(P 均 < 0.01 , vs 正常胃黏膜).

结论: TGF β II 型受体表达的减少可能在胃癌的发生发展中起了一定的作用.

张朋彬, 李宜辉, 徐采朴. 转化生长因子 β II 型受体在胃癌组织中表达的研究. *世界华人消化杂志* 2004;12(7):1531-1533

<http://www.wjgnet.com/1009-3079/12/1531.asp>

0 引言

转化生长因子 β (transforming growth factor β , TGF β)是一具有多功能的细胞因子^[1-4], 对细胞的生长分化具有重要的调节作用. 他可抑制多种细胞的生长, 并对一些肿瘤细胞具有生长抑制作用^[5-6]. 我们利用免疫组织化学方法, 对 TGF β II 型受体(TGF β II receptor, TGF β IIIR)在胃癌组织中的表达进行了研究如下.

1 材料和方法

1.1 材料 我院 1999/2001 年手术切除胃癌石蜡标本 74 例, 高分化腺癌 32 例, 低分化腺癌 23 例, 黏液腺癌 14 例, 印戒细胞癌 5 例. 男 54 例, 女 20 例, 平均年龄 57.4 岁. 以癌旁正常胃黏膜组织 20 例作为正常对照. 标本连续切 5 μ m 厚切片, 供 HE 染色及免疫组织化学用.

1.2 方法 免疫组织化学采用 ABC 法, TGF β IIIR 抗体(兔抗人, 即用型)及 ABC 试剂盒均购自武汉博士德公司. 切片常规脱蜡水化, 30 mL/L H₂O₂ 封闭内源性过氧化物酶, 胰酶消化, 正常血清封闭, 加入 TGF β IIIR 4 过夜, 生物素化羊抗兔 IgG 37 $^{\circ}$ C 孵育 20 min, ABC 37 $^{\circ}$ C 孵育 20 min, DAB 显色, 苏木素复染, 常规脱水、透明、封片. 以细胞质和 / 或细胞膜有棕黄色沉淀者为表达阳性细胞. 随机计数 100 个细胞, 观察其表达阳性率, 结果表示为无表达(-), 1-33% 阳性为(+), 34-66% 阳性为(++) >67% 阳性为(+++).

统计学处理 计数资料, 采用 χ^2 检验.

2 结果

在正常胃黏膜组织, 以腺体的颈部为界, TGF β IIIR 基




图1 A:正常胃黏膜组织, ABC × 100; 图B:高分化胃癌组织, ABC × 100; 图C: 低分化腺癌组织, ABC × 200.

本集中表达于腺体的中下部, 尤以壁细胞表达最为明显. 而在腺体表面的黏液细胞则几乎无表达(图1A). 在表达细胞中, TGFβIIIR 表达于细胞质及细胞膜上, 与TGFβ的表达非常相似. 在胃癌组织中, TGFβIIIR 的表达明显减少, 与正常胃黏膜组织相差非常显著(高中分化腺癌 $P < 0.05$, 低分化腺癌与黏液印戒细胞癌均 $P < 0.01$, 表1), 但与组织分化无关($P > 0.05$, 图1B, 图1C).

表1 TGFβIIIR 在正常胃黏膜组织及胃癌组织中的表达

组织学类型	n	TGFβIIIR 表达		
		+	++	+++
正常胃黏膜组织	20		13	7
高中分化腺癌 ^a	32	10	18	4
低分化腺癌 ^b	23	8	15	
黏液印戒细胞癌 ^b	19	11	8	

^a $P < 0.05$, ^b $P < 0.01$, vs 正常胃黏膜.

3 讨论

在信号传导时TGFβ首先与细胞膜上TGFβIIIR结合, 后者使I型受体加入这一复合体并被活化. 活化的受体通过激活细胞内Smad蛋白而将TGFβ信号传到细胞核. 在信号传导中, I型或II型受体的异常表达均可使TGFβ的信号传递中断或减弱^[7-9]. TGFβ除对正常细胞具有生长抑制作用外, 对癌细胞的生长也具有抑制作用, 并可引起癌细胞发生凋亡^[10-16]. 在肿瘤治疗中, 一些药物的部分疗效是通过诱导产生TGFβ而达到治疗目的的^[17-18]. 动物实验证明, TGFβ可抵抗化学诱癌剂的诱癌作用^[19]. 当TGFβIIIR表达异常, 造成TGFβ信号传递中断时, 则癌细胞就逃脱了TGFβ的抑制作用, 修复TGFβ信号后, 癌细胞又受到了TGFβ的抑制^[20-21].

表达异常的TGFβIIIR多是由于其基因709-718区的多聚腺苷酸Poly(A)₁₀中的腺苷酸的插入或缺失所造成. 该区域腺苷酸的插入或缺失, 使TGFβIIIR基因发生框架移动, 产生异常的II型受体或使其转录中断^[22-29]. 这种现象与微卫星不稳定性(microsatellite instability, MI)有关. 微卫星是指基因组中散在的较短的重复序列, 他在DNA复制时容易产生错配现象, 即易发生碱基的插

入或缺失, 这种错配可由体内的错配修复系统(mismatch repair, MMR)来纠正. 当该系统有缺陷, 不能纠正DNA的复制错误时, 便出现MI, 使相关基因自发突变率升高^[30-33]. Johansdottir et al^[34]发现, 在高MI患者TGFβIIIR突变率高达62%, 但该突变与肿瘤类型无关. 但也有研究发现, TGFβIIIR异常表达更多见于低分化腺癌及印戒细胞癌^[28]. Yang et al^[35]发现TGFβIIIR表达异常的胃癌细胞不受TGFβ抑制, 当对该细胞进行TGFβIIIR基因转染后, TGFβ又重新能够抑制该细胞的生长.

我们通过免疫组织化学方法, 发现在胃癌组织中, TGFβIIIR的表达明显减少($P < 0.01$), 说明TGFβ的信号传导出现了障碍, 阻断或减弱了TGFβ对胃癌细胞的生长抑制作用. 但TGFβIIIR的表达与胃癌组织分化程度无明显关系. TGFβIIIR表达的减少, 使胃细胞逃脱TGFβ的生长抑制作用, 对胃癌的发生发展起了一定的促进作用.

4 参考文献

- Xiong B, Gong LL, Zhang F, Hu MB, Yuan HY. TGF beta1 expression and angiogenesis in colorectal cancer tissue. *World J Gastroenterol* 2002;8:496-498
- Xiong B, Yuan HY, Hu MB, Zhang F, Wei ZZ, Gong LL, Yang GL. Transforming growth factor-beta1 in invasion and metastasis in colorectal cancer. *World J Gastroenterol* 2002;8:674-678
- Lu JP, Mao JQ, Li MS, Lu SL, Hu XQ, Zhu SN, Nomura S. In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis. *World J Gastroenterol* 2003;9:590-594
- Shen H, Huang GJ, Gong YW. Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation. *World J Gastroenterol* 2003;9:784-787
- Mehra A, Wrana JL. TGF-beta and the Smad signal transduction pathway. *Biochem Cell Biol* 2002;80:605-622
- 陈修熙, 来茂德. 转化生长因子TGF-beta研究进展. *世界华人消化杂志* 2000;8:1405-1409
- Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. *Science* 2002;296:1646-1647
- 张朋彬, 徐采朴. 转化生长因子β与胃癌. *华人消化杂志* 1998;6:630-631
- Pinto M, Oliveira C, Cirnes L, Carlos Machado J, Ramires M, Nogueira A, Carneiro F, Seruca R. Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas. *J Pathol* 2003;200:32-38
- Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, Takenoshita S. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7

- genes in colorectal cancer. *J Exp Clin Cancer Res* 2003;22:315-320
- 11 Wong SF, Lai LC. The role of TGF β in human cancers. *Pathology* 2001;33:85-92
- 12 Miyazono K, Suzuki H, Imamura T. Regulation of TGF- β signaling and its roles in progression of tumors. *Cancer Sci* 2003;94:230-234
- 13 Katakura Y, Nakata E, Tabira Y, Miura T, Teruya K, Tsuchiya T, Shirahata S. Decreased tumorigenicity in vivo when transforming growth factor β treatment causes cancer cell senescence. *Biosci Biotechnol Biochem* 2003;67:815-821
- 14 Yoo YD, Choi JY, Lee SJ, Kim JS, Min BR, Lee YI, Kang YK. TGF- β -induced cell-cycle arrest through the p21(WAF1/CIP1)-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells. *Int J Cancer* 1999;83:512-517
- 15 Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor β 1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. *Cancer Res* 1999;59:3379-3386
- 16 Reiss M. TGF- β and cancer. *Microbes Infect* 1999;1:1327-1347
- 17 Tavassoli M, Soltaninia J, Rudnicka J, Mashanyare D, Johnson N, Gaken J. Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF- β 1. *Carcinogenesis* 2002;23:1569-1575
- 18 Hoffmann TK, Bojar H, Eckel J, van Lierop A, Balz V, Friebe-Hoffmann U, Hauser U, Bier H. Effects of tamoxifen on human squamous cell carcinoma lines of the head and neck. *Anticancer Drugs* 2002;13:521-531
- 19 Salatino M, Labriola L, Schillaci R, Charreau EH, Elizalde PV. Mechanisms of cell cycle arrest in response to TGF- β in progesterin-dependent and -independent growth of mammary tumors. *Exp Cell Res* 2001;265:152-166
- 20 Franchi A, Gallo O, Sardi I, Santucci M. Downregulation of transforming growth factor β type II receptor in laryngeal carcinogenesis. *J Clin Pathol* 2001;54:201-204
- 21 Ramachandra M, Atencio I, Rahman A, Vaillancourt M, Zou A, Avanzini J, Wills K, Bookstein R, Shabram P. Restoration of transforming growth factor β signaling by functional expression of smad4 induces anoikis. *Cancer Res* 2002;62:6045-6051
- 22 Kim JJ, Baek MJ, Kim L, Kim NG, Lee YC, Song SY, Noh SH, Kim H. Accumulated frameshift mutations at coding nucleotide repeats during the progression of gastric carcinoma with microsatellite instability. *Lab Invest* 1999;79:1113-1120
- 23 Iacopetta BJ, Soong R, House AK, Hamelin R. Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF- β type II receptor, IGFBP receptor, and BAX genes. *J Pathol* 1999;187:428-432
- 24 Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G. A TGF β type II frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. *Cancer Immunol Immunother* 2001;50:469-476
- 25 房殿春, 周晓东, 罗元辉, 王东旭, 鲁荣, 杨仕明, 刘为纹. 胃癌微卫星不稳定性与抑癌基因杂合缺失. *世界华人消化杂志* 1999;7:479-481
- 26 Miyajima A, Asano T, Seta K, Asano T, Kakoi N, Hayakawa M. Loss of expression of transforming growth factor- β receptor as a prognostic factor in patients with renal cell carcinoma. *Urology* 2003;61:1072-1077
- 27 Kim JJ, Baek MJ, Kim L, Kim NG, Lee YC, Song SY, Noh SH, Kim H. Accumulated frameshift mutations at coding nucleotide repeats during the progression of gastric carcinoma with microsatellite instability. *Lab Invest* 1999;79:1113-1120
- 28 Takeno S, Wirtz HC, Lickvers K, Noguchi T, Scheven M, Willers R, Gabbert HE, Mueller W. Transforming growth factor β type II receptor expression in gastric cancer: evidence for two independent subgroups. *Anticancer Res* 2002;22:2247-2252
- 29 Nerlich AG, Sauer U, Ruoss I, Hagedorn HG. High frequency of TGF- β -receptor-II mutations in microdissected tissue samples from laryngeal squamous cell carcinomas. *Lab Invest* 2003;83:1241-1251
- 30 Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. *Cancer Res* 2002;62:2447-2454
- 31 Duval A, Hamelin R. Genetic instability in human mismatch repair deficient cancers. *Ann Genet* 2002;45:71-75
- 32 Oda S, Maehara Y, Sumiyoshi Y, Sugimachi K. Microsatellite instability in cancer: what problems remain unanswered? *Surgery* 2002;131(1 Suppl):S55-S62
- 33 康燕婕, 林娜, 振科. 胃癌中微卫星不稳定性及 DNA 错配修复系. *世界华人消化杂志* 2000;8:1139-1140
- 34 Johannsdottir JT, Jonasson JG, Bergthorsson JT, Amundadottir LT, Magnusson J, Egilsson V, Ingvarsson S. The effect of mismatch repair deficiency on tumorigenesis; microsatellite instability affecting genes containing short repeated sequences. *Int J Oncol* 2000;16:133-139
- 35 Yang HK, Kang SH, Kim YS, Won K, Bang YJ, Kim SJ. Truncation of the TGF- β type II receptor gene results in insensitivity to TGF- β in human gastric cancer cells. *Oncogene* 1999;18:2213-2219

World Journal of Gastroenterology 稿件管理

为了加快《World Journal of Gastroenterology, WJG》稿件管理的信息化、电子化进程,提高办刊质量,规范编辑工作流程,提高工作效率,我们成功开发了世界胃肠病学杂志社稿件管理系统,并于2003-04-15投入使用,来稿登记、稿件回执、稿件初审、二审(包括选择审稿专家和发送审稿通知书)、审稿意见、终审定稿、发送录用通知书、退稿、编辑加工、数据交换、网上投稿查询等,全部实现了自动生成,电子化处理。作者在WJG网上投稿查询系统内提交用户名(第一作者)和密码(文章编号)后可查询到稿件的处理状态,如编号、刊名、题名、作者、收稿日期、送审日期、接受日期、退稿日期、发票编号、待发表日期、入卷(期)和出版页码等在内的28个项目。